Melatonin for Sedative Withdrawal in Older Patients with Primary Insomnia: a Randomized Double-Blind Placebo-Controlled Trial

Abstract

We compared the efficacy of melatonin and placebo as adjuvants in the withdrawal of patients from long term temazepam, zopiclone or zolpidem (here ‘BZD’) use. Gradual dose reduction of BZDs combined with CRM or placebo, and psychosocial support produced high short term and moderate long term BZD abstinence. CRM showed no withdrawal benefit compared with placebo.